CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で128.28%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 51.29Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 51.29Mです。
適正水準
同社の最新のPEは-5.05で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は17.67M株で、前四半期比で16.58%減少しています。
PRFDXが保有
スター投資家PRFDXは本銘柄を1.25K株保有しています。